6 Reasons to Avoid Atea Pharmaceuticals
Termination of Collaboration with Roche Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), a clinical-stage biopharmaceutical company, announced the termination of its strategic collaboration with Roche (OTCQX: RHHBY), for the joint development of AT-527, intended for the treatment of COVID-19. The agreement will be terminated on February 10,2022 and...
